首页|术前SOX方案新辅助化疗治疗进展期胃癌的CT影像学评价分析

术前SOX方案新辅助化疗治疗进展期胃癌的CT影像学评价分析

扫码查看
目的 术前SOX方案新辅助化疗治疗进展期胃癌的CT影像学评价分析.方法 本次研究共纳入本院自2010年1月~2015年2月收治的33例进展期胃癌患者(术前替吉奥胶囊+注射用奥沙利铂辅助化疗),患者均在接受3个SOX方案化疗周期后再行外科手术,并以切除肿瘤为最终病理金标准,通过查阅统计患者化疗前、化疗周期结束后的CT影像学资料,将其与手术病理学资料进行对比分析,明确CT检查对SOX方案新辅助化疗治疗进展期胃癌疗效评价价值. 结果 经手术病理学明确,术前SOX方案新辅助化疗治疗进展期胃癌的有效率为33.33%,无效率66.67%;肿瘤体积减少率与病理分级的相关性最强(r=0.581,P<0.001);经ROC分析,肿瘤体积减少率的最佳AUC值为0.834,当肿瘤体积减少率36.94%作为评价SOX方案新辅助化疗的有效阀值时,其评价有效率的敏感度及特异性最佳,分别为74.62%、83.01%.结论 CT体积测量可作为评价术前SOX方案新辅助化疗治疗进展期胃癌疗效的可靠临床数据,对进展期胃癌患者的后期治疗具一定的指导作用.
CT imaging evaluation analysis of preoperative SOX regimen neoadjuvant chemotherapy in the treatment of advanced gastric cancer
Objective To evaluate and analyze the CT imaging of preoperative SOX regimen neoadjuvant chemotherapy in the treatment of advanced gastric cancer.Methods A total of 33 patients with advanced gastric cancer treated in our hospital from January 2010 to February 2015 were enrolled for the study and given tegafur gimeracil oteracil potassium capsule plus oxaliplatin for injection as preoperative adjuvant chemotherapy.And all the patients were given surgery after 3 cycles of SOX regimen chemotherapy, and surgical resection of the tumor was taken as the final pathology gold standard.The CT imaging data of the patients before and after the chemotherapy was counted and then analyzed and compared with the pathological data to clarify the value of CT imaging in the evaluation of SOX regimen neoadjuvant chemotherapy for advanced gastric cancer.Results The effective rate was 33.33% and the ineffective rate was 66.67% in the preoperative SOX regimen neoadjuvant chemotherapy for advanced gastric cancer through clear surgical pathology.The correlation between tumor volume reduction and pathological grading was the strongest(r=0.581, P<0.001).By ROC analysis, the best area value(AUC) of the tumor volume reduction rate was 0.834.When the tumor volume reduction rate with 36.94% was taken as the effective threshold for SOX regimen neoadjuvant chemotherapy, the sensitivity and specificity of the evaluation were the best with 74.62% and 83.01% respectively.Conclusion sCT volume measurement can be used as a reliable clinical data to evaluate the efficacy of preoperative SOX regimen neoadjuvant chemotherapy in the treatment of advanced gastric cancer and have certain guiding significance in the late treatment of patients with advanced gastric cancer.

SOX regimenneoadjuvant chemotherapyadvanced gastric cancerCT imaging

张建明、钟建国

展开 >

浙江省东阳市横店医院 放射科,浙江 东阳 322118

浙江省人民医院 放射科,浙江 杭州 310014

SOX方案 新辅助化疗 进展期胃癌 CT影像学

2017

中国生化药物杂志
南京生物化学制药研究所,全国生化制药情报中心站,中国生化制药工业协会,中国药品生物制品检定所

中国生化药物杂志

ISSN:1005-1678
年,卷(期):2017.(7)
  • 1
  • 6